

Special Issue

Cancer Molecular Biology and Drug Discovery

Message from the Guest Editor

Cancer is a major health issue worldwide, with an increasing global burden in the coming years. Some malignancies, such as colorectal, breast, prostate, and pancreatic cancers, are still incurable in advanced stages. Thus, more effective anticancer drugs are always urgently needed. The process of drug discovery is still risky, lengthy, and costly, and only a few new anticancer drugs have received approval in recent years. Drug repurposing is an unconventional drug discovery approach to explore new disease indications from existing clinical drugs. Exploring polypharmacology is highly useful for discovering drugs' novel MOAs to improve their therapeutic efficacies and treat different diseases. The advantages of drug repurposing include a reduction in cost and the bypass of safety concerns because extensive drug data are often available. This Special Issue will focus on the development of novel cancer therapy based on polypharmacology and drug repurposing strategies. We welcome original research articles and review articles in this field.

Guest Editor

Prof. Dr. Pei-Ming Yang

Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan

Deadline for manuscript submissions

closed (31 January 2024)



BioChem

an Open Access Journal
by MDPI

CiteScore 2.9
Tracked for Impact Factor



mdpi.com/si/110373

BioChem
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biochem@mdpi.com

[mdpi.com/journal/
biochem](https://mdpi.com/journal/biochem)





BioChem

an Open Access Journal
by MDPI

CiteScore 2.9
Tracked for Impact Factor



[mdpi.com/journal/
biochem](https://mdpi.com/journal/biochem)



About the Journal

Message from the Editor-in-Chief

The advances of biological science have fundamentally changed our world and our understanding of human beings. All the progress, from a simple biochemical reaction to systems biology, has come from interdisciplinary interactions in a variety of scientific fields. This is especially true and important for the current and future study of a broad range of biochem topics, the core of biological science.

Editor-in-Chief

Prof. Dr. Buyong Ma
School of Pharmacy, Shanghai Jiaotong University, Shanghai, China

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within ESCI (Web of Science), Scopus, EBSCO and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 33.9 days after submission; acceptance to publication is undertaken in 3.8 days (median values for papers published in this journal in the second half of 2025).